Objective:To investigate the clinical efficacy of insulin degludec and insulin aspart combined with dapagliflozin in the treatment of type 2 diabetics with poor glycemic control.Methods:A total of 60 patients with type 2 diabetes mellitus and poor glycemic control admitted to the department of endocrinology in Sheyang County People's Hospital from April 2023 to September 2023 were enrolled.All of the patients were randomly divided into aspartate 30 group(subcutaneous injection of insulin aspartate 30 combined with oral dapagliflozin)and degludec aspartate group(subcutaneous injection of insulin degludec and insulin aspart combined with oral dapagliflozin),with 30 cases in each group.The blood glucose level,average blood glucose,standard deviation of blood glucose,fluctuation range of blood glucose,time to reach the standard of blood glucose control and insulin dose were compared between the two groups at the time of pre-breakfast,pre-lunch,pre-dinner and pre-bedtime.Results:After achieving glycemic control,the fasting blood glucose[(6.17±1.71)mmol/L vs(6.78±0.23)mmol/L],blood glucose standard deviation[(1.48±0.31)mmol/L vs(1.64±0.28)mmol/L]and blood glucose fluctuation range[(3.04±0.82)mmol/L vs(3.88±0.67)mmol/L]and time to achieve glycemic control[(6.00±2.00)days vs(7.13±1.66)days]of degludec aspartate group were significantly lower than those in aspartate 30 group(all P＜0.05).Conclusion:Insulin degludec and insulin aspart combined with dapagliflozin has a good therapeutic effect on type 2 diabetics with inadequate glycemic control,and it is worthy of clinical application.
insulin degludec and insulin aspartinsulin aspartate 30dapagliflozintype 2 diabetesinadequate glycemic control
维普
万方数据
